REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.
To order the test, physicians may contact 1-888-522-7971, or visit the company's website http://www.rosettagenomics.com.
"I am very excited to finally see a molecularly-based test that can
objectively differentiate mesothelioma from several types of carcinomas in
the lung with such high level of accuracy" noted Harvey Pass, MD, Division
Chief for Thoracic Surgery and Thoracic Oncology at the
Malignant pleural mesothelioma is directly linked to exposure to asbestos particles, as well as to various heavy metals. Rescue workers, shipyard workers, and miners are at increased risk of developing mesothelioma. Currently, there is no single diagnostic test that is entirely conclusive for this differentiation. In addition, pathological diagnosis may suffer from significant inter-observer variability, and in the absence of a single specific and reliable test, mesothelioma can be difficult to identify from other cancers.
miRview(TM) meso differentiates mesothelioma, a cancer connected to
asbestos exposure, from other carcinomas in the lung. Currently, there is no
single diagnostic test that is entirely conclusive for this differe
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved